<DOC>
	<DOCNO>NCT00466713</DOCNO>
	<brief_summary>This study investigate effect rosiglitazone , medicine commonly use treat type 2 diabetes , utilization glucose heart patient heart failure due heart attack . The primary purpose study determine whether treatment insulin-sensitizing medication improve heart 's ability metabolize glucose ( sugar ) .</brief_summary>
	<brief_title>Defining Role Insulin Resistance 'Idiopathic ' Dilated Cardiomyopathy</brief_title>
	<detailed_description>Nondiabetic patient nonischemic cardiomyopathy insulin-resistance insulin-sensitive base fasting homeostasis model assessment ( HOMA ) value eligible trial . At baseline , 6-minute walk test perform , follow assessment coronary flow reserve ammonia-PET imaging before/after adenosine infusion . Subjects give oral glucose load ( 75g ) , follow PET image F-18-fluoro-2-deoxyglucose ( FDG ) . Subjects begin take rosiglitazone 4 mg qd x 12 week , 6-minute walk test &amp; PET imaging repeat .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Diagnosis nonischemic dilate cardiomyopathy , current NYHA class III congestive heart failure History Stage CD heart failure EF â‰¤ 40 % course disease Treatment stable comprehensive heart failure regimen least 3 month ( include betablockers ACEinhibitors angiotensin receptor blocker unless intolerant ) Age &gt; 18 yr Cardiomyopathy due one following : Ischemic heart disease Primary valvular lesion Hypertrophic cardiomyopathy Cardiac resynchronization within last 3 month Transaminase value &gt; 2.5 x upper limit normal history liver disease Diagnosis diabetes mellitus : Diabetes previously diagnose per patient history 2 fast glucose value &gt; 125 mg/dl Current NYHA class III IV heart failure Serum creatinine &gt; 1.6 mg/dl History heart transplantation Pregnancy active breast feeding Hospitalization decompensated heart failure within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Nonischemic dilate cardiomyopathy</keyword>
</DOC>